A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- Cobolimab
- Conditions
- Neoplasms
- Sponsor
- GlaxoSmithKline
- Enrollment
- 107
- Locations
- 1
- Primary Endpoint
- Number of participants with dose-limiting toxicities (DLTs)
- Status
- Active, not recruiting
- Last Updated
- 6 months ago
Overview
Brief Summary
This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants. The study may assess the PK/PD cohorts for Arm E and/or Arm F in participants outside of China and Japan. Additionally, dostarlimab will be given in combination with cobolimab in Japanese participants. Drug name mentioned as belrestotug, GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as belrestotug.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults 18 years of age or older (or \>=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan)
- •Female participants of childbearing potential must agree to use a highly effective form of contraception
- •Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy. Enrollment in PK/PD cohorts will be restricted to participants with histologically or cytologically confirmed diagnosis of 1 or more of the following: non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer (EC), colorectal cancer (CRC) (including specified molecular subtypes of these) or an alternative immunogenic tumor type with medical monitor approval
- •Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists
- •Participants in a PK/PD cohort (Arms A, B, E and F) must provide fresh tumor biopsies. Biopsies are not required from participants enrolled in Arm D, Arm E, (non-PK/PD cohorts only), Arm F (non-PK/PD cohort only), Arm G or any participant enrolled in mainland China
- •Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1
- •Life expectancy of at least 12 weeks
- •Adequate organ function as determined by laboratory assessments
- •Adequate cardiac ejection fraction as measured by echocardiogram
- •Arm A-Japan, Arm D-Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese
Exclusion Criteria
- •Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter
- •Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation
- •Toxicity from previous anticancer treatment, including; greater than or equal to (\>=) Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved; or history of myocarditis of any grade during a previous treatment with immunotherapy
- •Known additional malignancy that progressed or required active treatment within the last 2 years
- •Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis
- •Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years
- •Concurrent medical condition requiring the use of systemic immunosuppressive treatment
- •Cirrhosis or current unstable liver or biliary disease per investigator assessment
- •Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- •Prolonged QT as measured by electrocardiogram
Arms & Interventions
Participants receiving dostarlimab plus cobolimab (Arm G)
Participants will be administered an IV infusion of cobolimab followed by dostarlimab
Intervention: Cobolimab
Participants receiving GSK6097608 monotherapy (Arm A)
Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
Intervention: GSK6097608
Participants receiving GSK6097608 plus dostarlimab (Arm B)
Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
Intervention: GSK6097608
Participants receiving GSK6097608 plus dostarlimab (Arm B)
Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
Intervention: Dostarlimab
Participants receiving dostarlimab monotherapy (Arm D)
Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
Intervention: Dostarlimab
Participants receiving dostarlimab plus belrestotug (Arm E)
Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks.
Intervention: Dostarlimab
Participants receiving dostarlimab plus belrestotug (Arm E)
Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks.
Intervention: Belrestotug
Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)
Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.
Intervention: GSK6097608
Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)
Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.
Intervention: Dostarlimab
Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F)
Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks.
Intervention: Belrestotug
Participants receiving dostarlimab plus cobolimab (Arm G)
Participants will be administered an IV infusion of cobolimab followed by dostarlimab
Intervention: Dostarlimab
Outcomes
Primary Outcomes
Number of participants with dose-limiting toxicities (DLTs)
Time Frame: Up to Day 21
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 2 years
Secondary Outcomes
- Arms B, D, E, F, G: Cmax for dostarlimab(Up to 2 years)
- Arms B, D, E, F, G: AUC(0-infinity) for dostarlimab(Up to 2 years)
- Arms B, D, E, F, G: t1/2 for dostarlimab(Up to 2 years)
- Arms E, F: Cmax for belrestotug(Up to 2 years)
- Arms E, F: AUC(0-infinity) for belrestotug(Up to 2 years)
- Arms D, E, F, G: Progression-free survival (PFS) based on RECIST 1.1(Up to 2 years)
- Arms B, D, E, F, G: Number of participants with positive ADAs against dostarlimab(Up to 2 years)
- Number of participants with dose reductions or delay(Up to 2 years)
- Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1(Up to 2 years)
- Arms D, E, F, G: DCR based on iRECIST(Up to 2 years)
- Arms D, E, F, G: DOR based on iRECIST(Up to 2 years)
- Arm G: Number of participants with positive ADAs against cobolimab(Up to 2 years)
- Arms A, B, F: Minimum observed concentration (Cmin) for GSK6097608(Up to 2 years)
- Arms A, B, F: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) for GSK6097608(Up to 2 years)
- Arms D, E, F, G: Disease Control Rate (DCR) based on RECIST 1.1(Up to 2 years)
- Arms D, E, F, G: Duration of response (DOR) based on RECIST 1.1(Up to 2 years)
- Arms A, B, F: Titers of ADAs against GSK6097608(Up to 2 years)
- Arms A, B, F: Maximum observed concentration (Cmax) for GSK6097608(Up to 2 years)
- Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings(Up to 2 years)
- Arms D, E, F, G: ORR based on modified Response Evaluation Criteria in Solid Tumors (iRECIST)(Up to 2 years)
- Arms D, E, F, G: Time to response (TTR) based on RECIST 1.1(Up to 2 years)
- Arms D, E, F, G: PFS based on iRECIST(Up to 2 years)
- Arms B, D, E, F, G: Titers of ADAs against dostarlimab(Up to 2 years)
- Arms E, F: Number of participants with positive ADAs against belrestotug(Up to 2 years)
- Arms E, F: Titers of ADAs against belrestotug(Up to 2 years)
- Arms A, B, F: Apparent terminal phase half-life (t1/2) for GSK6097608(Up to 2 years)
- Number of participants withdrawn due to AEs(Up to 2 years)
- Arms D, E, F, G: TTR based on iRECIST(Up to 2 years)
- Arms A, B, F: Number of participants with positive anti-drug antibodies (ADAs) against GSK6097608(Up to 2 years)
- Arm G: Titers of ADAs against cobolimab(Up to 2 years)
- Arms A, B, F: Area under the plasma concentration-time curve from time zero to time (AUC[0-t]) for GSK6097608(Up to 2 years)
- Arms B, D, E, F, G: Cmin for dostarlimab(Up to 2 years)
- Arm G: Cmax for cobolimab(Up to 2 years)
- Arms E, F: Cmin for belrestotug(Up to 2 years)
- Arm G: AUC(0-infinity) for cobolimab(Up to 2 years)
- Arms B, D, E, F, G: AUC(0-t) for dostarlimab(Up to 2 years)
- Arms E, F: AUC(0-t) for belrestotug(Up to 2 years)
- Arms E, F: t1/2 for belrestotug(Up to 2 years)
- Arm G: Cmin for cobolimab(Up to 2 years)
- Arm G: t1/2 for cobolimab(Up to 2 years)
- Arm G: AUC(0-t) for cobolimab(Up to 2 years)